Pig Lung Xenotransplantation: Barriers on the Road to Clinical Translation
Transplant International · 2026
DOI: 10.3389/ti.2025.15542 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant International, 2026. Verfasst von Sho Takemoto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States. Hauptthemen laut MEDLINE: Transplantation, Heterologous, Lung Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Lungs remain one of the most difficult solid organs for xenotransplantation, owing to its delicate alveolar capillary barrier and intense crosstalk between innate immunity and coagulation system. Multi-gene-engineered donor pig organs combined with co-stimulation pathway blockade based immunosuppressive regimen have extended xenograft survival in preclinical models using non-human primates (NHP) from hours to weeks. Most recently, the first case of lung xenotransplantation into a brain-dead human recipient was reported, confirming technical feasibility without hyperacute rejection while revealing early inflammatory injury and progressive dysfunction. Key barriers include loss of vascular barrier function, dysregulated coagulation and platelet function driven by porcine-human molecular incompatibilities, and antibody-mediated injury. Preclinical data implicate innate immune activation such as natural killer cells and macrophages. Unlike kidney xenotransplantation, which has achieved stable long-term outcomes in NHPs, lungs require attention to immunogenicity against the “fourth antigen” in triple-knockout (TKO) donors that include the positive crossmatch created by the CMAH deletion when TKO organs are tested in NHP. Although consistent multi-month lung xenograft survival has not yet been achieved in preclinical models, the remaining barriers to clinical translation are being defined. This review delineates lung-specific xeno-immune mechanisms and advances aimed at their mitigation, providing insights necessary for future clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Transplantation Sciences, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Förderung
- NIAID NIH HHS
- NIH HHS
Zitieren
APA
Takemoto, S., Burdorf, L., & Pierson, R. N. (2026). Pig Lung Xenotransplantation: Barriers on the Road to Clinical Translation. Transplant International. https://doi.org/10.3389/ti.2025.15542
Vancouver
Takemoto S, Burdorf L, Pierson RN. Pig Lung Xenotransplantation: Barriers on the Road to Clinical Translation. Transplant International. 2026. doi:10.3389/ti.2025.15542
BibTeX
@article{Takemoto2026,
author = {Takemoto, Sho and Burdorf, Lars and Pierson, Richard N},
title = {Pig Lung Xenotransplantation: Barriers on the Road to Clinical Translation},
journal = {Transplant International},
year = {2026},
doi = {10.3389/ti.2025.15542}
}
EUVIMED